MedTrace Logo

Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity

NCT01296815 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2015-07-27

Study results available
· View outcomes & findings →

Summary

Kaposi sarcoma remains the most common malignancy among persons with HIV.

Lesions localized to the airway may cause bleeding, pain and dyspnea.

New therapeutic approaches for local disease are needed.

The purpose of this study is to compare the effectiveness of intralesional bevacizumab + HAART vs HAART alone in treating localized Kaposi´s sarcoma of the airway in patients with AIDS.

Conditions

  • Kaposi´s Sarcoma

Interventions

DRUG

Bevacizumab

Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3

Sponsors & Collaborators

  • Centro de Investigación en. Enfermedades Infecciosas, Mexico

    lead OTHER_GOV

Principal Investigators

  • Gustavo Reyes-Teran, M.D. · Centro de Investigacion en Enfermedades Infecciosas

  • Yuria Ablanedo-Terrazas, M.D. · Centro de Investigacion en Enfermedades Infecciosas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2012-12-31
Completion
2013-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01296815 on ClinicalTrials.gov